- MD: Hacettepe University, Turkey
- D.Phil: University of Oxford, UK
- Postdoctoral Studies: NIH, member of the Laboratory of Immune System Biology, NIAID
Research Interests: Multiple Sclerosis (MS) and Neuroimmunology
Dr. Akkaya studies the mechanisms of regulatory T cell (Treg) mediated immune suppression in the context of autoimmunity and cancer using state-of-the-art techniques. Her lab is currently funded by the NIAID New Innovators Award (DP2) for exploring new precision therapies for autoimmune diseases and solid tumors.
Project 1: Deciphering the antigen mediated interactions and suppression mechanisms of human Tregs.
This project aims to implement a novel pipeline to reveal the specificities of dominant autoreactive effector T cell and Treg clones derived from type 1 diabetes mellitus and multiple sclerosis patients. The overarching goal of this study is to devise new antigen-targeted adoptive Treg therapies for autoimmune diseases.
Project 2: Discovering the molecular machinery underlying Treg interactions and Treg-mediated suppression.
This project aims to elucidate the signals provided to Tregs via antigen mediated contacts with dendritic cells. We compare Tregs and effector T cells using conventional techniques such as phosphoflow and western blot while also performing an unbiased analysis of phosphoproteome, to decipher the pathways underlying antigen- MHC Class II capture and antigen-specific suppression. Overall, this project will uncover the molecular basis of antigen-specific suppression performed by Tregs and identify key molecules that can potentially be targeted to fine-tune the Treg activity in autoimmunity and cancer.
Project 3: Determining the antigen-presentation capability of antigen-specific Tregs post- primary immune synapse.
In this project we focus on the events after Treg-APC synapse and investigate whether capturing antigen- MHC Class II (pMHCII) equips Tregs with the unique ability to target helper T cells during the physical absence of dendritic cells. We perform live confocal and intravital two-photon microscopy imaging as well as flow cytometry 1) to quantify direct contact between Tregs and helper T cells post-pMHCII acquisition 2) to determine modes of paracrine communication. Altogether, the findings from this project will describe how the Treg-T cell interactions shape peripheral tolerance and what mechanisms additional to pMHCII depletion are in place to prevent autoimmunity and also to promote tumor development.
For training and job opportunities, please contact firstname.lastname@example.org.
Office: BRT, 620
Lab: BRT, 660
Trainees at undergraduate, graduate and postdoctoral levels are welcome to apply!
Currently available jobs:
Please visit https://hr.osu.edu/careers/ and enter the requisition numbers below. If you have questions or difficulty in applying via the HR platform please reach out to email@example.com.
Postdoctoral fellow: R33797
Research associate 2: R33794
Research associate 1: R33792
Research technician 2: R33795